MX2015003407A - Formulaciones orales de angiotensina. - Google Patents

Formulaciones orales de angiotensina.

Info

Publication number
MX2015003407A
MX2015003407A MX2015003407A MX2015003407A MX2015003407A MX 2015003407 A MX2015003407 A MX 2015003407A MX 2015003407 A MX2015003407 A MX 2015003407A MX 2015003407 A MX2015003407 A MX 2015003407A MX 2015003407 A MX2015003407 A MX 2015003407A
Authority
MX
Mexico
Prior art keywords
angiotensin
oral formulations
present
provides various
oral delivery
Prior art date
Application number
MX2015003407A
Other languages
English (en)
Inventor
Richard Franklin
William Stern
Austin Vryhof
Original Assignee
Tarix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarix Pharmaceuticals Ltd filed Critical Tarix Pharmaceuticals Ltd
Publication of MX2015003407A publication Critical patent/MX2015003407A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

La presente invención proporciona varias formulaciones para la administración oral de péptidos angiotensina.
MX2015003407A 2012-09-17 2013-09-17 Formulaciones orales de angiotensina. MX2015003407A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261701972P 2012-09-17 2012-09-17
PCT/US2013/060139 WO2014043693A1 (en) 2012-09-17 2013-09-17 Oral formulations of angiotensin

Publications (1)

Publication Number Publication Date
MX2015003407A true MX2015003407A (es) 2015-10-14

Family

ID=50278763

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003407A MX2015003407A (es) 2012-09-17 2013-09-17 Formulaciones orales de angiotensina.

Country Status (13)

Country Link
US (1) US20150246093A1 (es)
EP (1) EP2895154A4 (es)
JP (1) JP2015529684A (es)
KR (1) KR20150065736A (es)
CN (1) CN104853749A (es)
AU (1) AU2013315004A1 (es)
BR (1) BR112015005738A2 (es)
CA (1) CA2884792A1 (es)
HK (1) HK1213785A1 (es)
IN (1) IN2015DN03132A (es)
MX (1) MX2015003407A (es)
RU (1) RU2015108678A (es)
WO (1) WO2014043693A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102294577B1 (ko) * 2015-01-12 2021-08-26 엔터리스 바이오파마, 인크. 고체 경구 제형
US10829519B2 (en) 2015-09-18 2020-11-10 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
WO2023063376A1 (ja) * 2021-10-13 2023-04-20 中外製薬株式会社 ペプチド化合物及び界面活性剤を含む組成物
WO2023214509A1 (ja) * 2022-05-02 2023-11-09 中外製薬株式会社 界面活性剤と併用するためのペプチド化合物を含む組成物
WO2024080308A1 (ja) * 2022-10-12 2024-04-18 中外製薬株式会社 ペプチド、界面活性剤及びポリマーを含む組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2475953A1 (en) * 2002-02-27 2003-09-04 E. Ann Tallant Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
US20080199434A1 (en) * 2006-11-13 2008-08-21 Board Of Trustees Of The University Of Arkansas Compositions and methods for the treatment of cardiovascular conditions
US8377863B2 (en) * 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
BRPI0800585B8 (pt) * 2008-02-13 2021-05-25 Univ Minas Gerais composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
ES2393455T3 (es) * 2008-09-12 2012-12-21 Charité-Universitátsmedizin Berlin (Charité) Uso de un agonista del receptor Ang-(1-7) en lesiones pulmonares agudas
CN105581984A (zh) * 2009-04-09 2016-05-18 阿尔科米斯制药爱尔兰有限公司 药物递送组合物
KR101514414B1 (ko) * 2011-02-02 2015-05-04 유니버시티 오브 써던 캘리포니아 당뇨병성 족부 궤양의 치료방법

Also Published As

Publication number Publication date
WO2014043693A1 (en) 2014-03-20
EP2895154A4 (en) 2016-04-20
EP2895154A1 (en) 2015-07-22
RU2015108678A (ru) 2016-11-10
HK1213785A1 (zh) 2016-07-15
JP2015529684A (ja) 2015-10-08
CA2884792A1 (en) 2014-03-20
US20150246093A1 (en) 2015-09-03
AU2013315004A1 (en) 2015-04-02
BR112015005738A2 (pt) 2017-08-08
IN2015DN03132A (es) 2015-10-02
CN104853749A (zh) 2015-08-19
KR20150065736A (ko) 2015-06-15

Similar Documents

Publication Publication Date Title
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
JO3755B1 (ar) تركيبات تستوستيرون
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
IN2015DN00127A (es)
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
MY172292A (en) Vectors and sequences for the treatment of diseases
AU2013337247A8 (en) XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
HK1221653A1 (zh) 用於呼吸遞送三種或更多種活性劑的組合物、方法和系統
MY168300A (en) Pharmaceutical Composition for Inhalation
TN2014000136A1 (en) Selective androgen receptor modulators
IN2014DN09450A (es)
HK1216720A1 (zh) 用於遞送治療劑的可生物蝕解的硅基組合物
IN2015DN03132A (es)
HK1208188A1 (en) Formulations for the delivery of active ingredients
IN2014CN00312A (es)
MY165088A (en) Pharmaceutical compositions comprising alisporivir
GEP201706636B (en) Galactagogue compositions based on phosphatidylserine
IN2014DN10209A (es)
GB2509470A (en) Pharmaceutical compositions of antihypertensives
TN2013000218A1 (en) Pharmaceutical compositions comprising alisporivir
MX2015001134A (es) Compuestos terapeuticos.
IN2013CH05395A (es)
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA72478U (ru) Применение полентара как средства фригопротекторного действия
IN2012DE01204A (en) "shikhar technology"